Last updated: July 31, 2026
Lupron Depot-PED Kit is a leuprolide acetate injectable used to suppress premature puberty in children with central precocious puberty. The product has a mature regulatory profile, limited label-expansion activity, and declining competitive protection relative to newer long-acting therapies. Its commercial position depends on physician familiarity, pediatric endocrinology access, payer coverage, depot-administration infrastructure, and the absence of a broadly substitutable generic depot product.
What is Lupron Depot-PED Kit?
Lupron Depot-PED Kit contains leuprolide acetate, a gonadotropin-releasing hormone agonist. Continuous exposure initially stimulates and then suppresses pituitary gonadotropin secretion, reducing luteinizing hormone and follicle-stimulating hormone activity. The resulting reduction in sex-steroid production delays further progression of central precocious puberty.
The product is supplied as a sterile microsphere formulation that is reconstituted before intramuscular administration. The pediatric depot presentations include:
| Presentation |
Typical administration interval |
Clinical use |
| 7.5 mg |
Every month |
Central precocious puberty |
| 11.25 mg |
Every month |
Central precocious puberty |
| 15 mg |
Every month |
Central precocious puberty |
| 11.25 mg |
Every three months |
Central precocious puberty |
| 30 mg |
Every three months |
Central precocious puberty |
The product is distinct from Lupron Depot formulations marketed for prostate cancer, endometriosis and uterine fibroids. Dose, labeling, administration requirements and patient populations differ.
The U.S. product is associated with NDA 020263 and is marketed within the Lupron Depot franchise. The FDA label identifies leuprolide acetate as the active ingredient and central precocious puberty as the pediatric indication.[1]
What is the FDA regulatory status of Lupron Depot-PED Kit?
Lupron Depot-PED is an FDA-approved therapy for children with central precocious puberty. Its regulatory status is post-approval rather than development-stage. The key regulatory requirements are treatment confirmation, appropriate dosing by age and weight-related clinical factors, and monitoring of pubertal progression and treatment response.
The label includes warnings and precautions relating to:
- Initial hormonal stimulation after treatment begins
- Vaginal bleeding during the first weeks of therapy
- Injection-site reactions
- Convulsions, including reported risk in susceptible patients
- Psychiatric events
- Reduced bone mineral density during treatment
- Hypersensitivity reactions
- Potential errors in preparation or administration
The label also requires attention to treatment discontinuation and the timing of pubertal recovery. Pubertal progression generally resumes after suppression is withdrawn, although the timing varies by patient.
How does Lupron Depot-PED compare with Fensolvi?
Fensolvi is also a leuprolide acetate product for central precocious puberty. It uses a six-month subcutaneous depot formulation, while Lupron Depot-PED relies on monthly or three-month intramuscular administration. Fensolvi was approved by the FDA in 2020.[2]
| Attribute |
Lupron Depot-PED |
Fensolvi |
| Active ingredient |
Leuprolide acetate |
Leuprolide acetate |
| Delivery route |
Intramuscular |
Subcutaneous |
| Longest labeled interval |
Three months |
Six months |
| Indication |
Central precocious puberty |
Central precocious puberty |
| Product type |
Microsphere depot |
Extended-release injectable |
| Administration burden |
Higher |
Lower |
| Main commercial advantage |
Long clinical history and familiarity |
Longer dosing interval |
Fensolvi competes directly for patients and prescribers but is not an automatic generic substitute for Lupron Depot-PED. Differences in route, formulation, device or administration interval can limit pharmacy-level substitution.
What clinical trials are evaluating Lupron Depot-PED?
The pivotal efficacy program for leuprolide in central precocious puberty is complete. Current clinical activity is more likely to involve treatment monitoring, long-term outcomes, disease registries and comparisons among GnRH agonist products than a new registration trial for Lupron Depot-PED.
Historical clinical evidence established that depot leuprolide suppresses gonadotropin secretion, slows secondary sexual development and reduces the rate of skeletal maturation in children with central precocious puberty. Treatment decisions generally incorporate:
- Age at onset
- Bone age advancement
- Growth velocity
- Predicted adult height
- Tanner stage
- Basal and stimulated LH levels
- Brain imaging and assessment for underlying causes
Clinical trial activity in the broader disease category has shifted toward newer dosing schedules and alternative delivery systems. The most commercially relevant development has been longer-acting treatment, including six-month leuprolide and six-month histrelin or triptorelin-based options.
What is the current clinical development outlook?
No major new Lupron Depot-PED registration program is central to the product’s commercial outlook. The likely clinical priorities are:
- Long-term safety surveillance.
- Comparative evidence on treatment adherence and injection burden.
- Real-world persistence and treatment completion.
- Pediatric endocrine outcomes, including adult-height and bone-health measures.
- Health-economic studies comparing monthly, three-month and six-month products.
A label expansion would be difficult to justify unless it improved dosing convenience, demonstrated a meaningful clinical advantage or addressed an underserved pediatric endocrine population.
When does Lupron Depot-PED lose exclusivity?
Lupron Depot-PED has a mature exclusivity profile. The original compound, early depot formulations and historic regulatory exclusivities are no longer the primary commercial barrier. Current protection depends on any unexpired formulation, manufacturing, method-of-use or device-related rights, together with regulatory and technical barriers to producing a pharmaceutical-grade depot microsphere injection.
FDA regulatory exclusivity and patent exclusivity are separate. Pediatric exclusivity, if previously granted for a qualifying study, would have expired long before the current commercial period. A generic applicant would generally need to address the relevant Orange Book-listed patents through an ANDA certification process.
What is the Orange Book status of Lupron Depot-PED?
The FDA Orange Book should be assessed by NDA, strength and dosage form because listings can differ across presentations and supplements. The relevant review should identify:
- Active patent listings associated with NDA 020263
- Expiration dates
- Patent-use codes
- Whether any listed patent covers the pediatric indication
- Whether a three-month or monthly presentation has separate listings
- Any applicable pediatric exclusivity or regulatory exclusivity notation
The commercial significance of an Orange Book patent depends on its scope and on whether an ANDA applicant can certify paragraph IV, submit a section viii statement, or design around the listed claim.
What generic entry risks exist for Lupron Depot-PED?
Generic entry risk is moderate over the long term but technically higher than for a conventional immediate-release injectable. The product is a complex depot formulation with manufacturing variables that can affect release kinetics and clinical performance.
A generic competitor would need to control:
- Microsphere particle size
- Polymer composition and degradation
- Drug loading
- Reconstitution behavior
- Injection force
- Initial burst release
- Monthly or three-month release profile
- Sterility and endotoxin limits
- Stability after manufacturing and reconstitution
- Dose uniformity
- Suspension characteristics
A leuprolide acetate injection that does not reproduce the depot profile would not be a direct substitute. The regulatory pathway may also be affected by formulation complexity and the FDA’s requirements for demonstrating pharmaceutical equivalence and bioequivalence.
Could an authorized generic launch?
An authorized generic could reduce price pressure without requiring an independent competitor to solve the formulation and manufacturing problem. The commercial effect would depend on whether the product is sold under the same label, through specialty distribution, or under a separate generic label.
The most plausible generic-entry sequence is:
| Stage |
Commercial effect |
| Paragraph IV filing |
Legal uncertainty and payer preparation |
| First approved ANDA |
Limited launch potential if litigation remains unresolved |
| Authorized generic or settlement launch |
Price erosion with controlled channel access |
| Multiple depot generics |
Greater erosion and formulary pressure |
| Newer six-month products |
Continued share migration despite generic availability |
Which companies compete with Lupron Depot-PED?
The principal competitors are other GnRH agonist products used in central precocious puberty.
| Product |
Company |
Active ingredient |
Dosing profile |
Competitive position |
| Lupron Depot-PED |
AbbVie |
Leuprolide acetate |
Monthly or three-month |
Established incumbent |
| Fensolvi |
Tolmar Pharmaceuticals |
Leuprolide acetate |
Six-month |
Lower administration burden |
| Supprelin LA |
Endo Pharmaceuticals |
Histrelin acetate |
Annual implant |
Lowest routine dosing frequency |
| Triptodur |
Arbor Pharmaceuticals, now associated with Assertio’s commercial portfolio |
Triptorelin pamoate |
Six-month |
Long-acting injectable alternative |
| Vantas and other leuprolide products |
Various companies |
Leuprolide acetate |
Different indications |
Not direct pediatric substitutes |
Supprelin LA competes through annual implantation but requires a minor surgical procedure. Fensolvi and Triptodur compete more directly with Lupron Depot-PED on administration convenience.
How strong is the Lupron Depot-PED patent estate?
The patent estate is commercially mature rather than newly expanding. The strongest remaining barriers are likely to be formulation know-how, manufacturing scale, product quality systems and physician-channel relationships rather than broad composition-of-matter protection.
Formulation patents
Depot microsphere formulations can be protected by claims directed to:
- Biodegradable polymer matrices
- Drug-to-polymer ratios
- Particle-size distributions
- Release-duration profiles
- Reconstitution vehicles
- Stabilizers and excipients
- Manufacturing processes
- Lyophilization and storage conditions
The practical strength of these rights depends on claim breadth and whether a competitor can use a different polymer system or process while achieving a comparable clinical duration.
Method-of-use patents
Method-of-use protection may cover suppression of central precocious puberty, dosing schedules or treatment of specific pediatric populations. Older method claims are more vulnerable to expiration and invalidity challenges than newer formulation claims.
The pediatric indication also creates a substitution issue. An ANDA applicant may challenge a listed method patent with a paragraph IV certification or omit the protected use through a section viii statement, depending on the patent-use code and the scope of the proposed label.
What patent litigation affects Lupron Depot-PED?
The principal litigation risk would arise from an ANDA applicant filing a paragraph IV certification against an unexpired Orange Book-listed patent. A successful paragraph IV challenge could permit an earlier generic launch, subject to the 30-month stay, court outcomes, settlement terms and any exclusivity awarded to the first qualifying ANDA filer.
The relevant litigation questions are:
- Has an ANDA applicant served a paragraph IV notice?
- Was an infringement action filed within 45 days?
- Does a 30-month stay apply?
- Is the challenged patent a formulation, process or method patent?
- Does the proposed generic omit any patented use?
- Has the parties’ settlement allowed a licensed entry date?
- Are there later patents that could support a second enforcement action?
No litigation conclusion should be drawn from the existence of an Orange Book listing alone. Claim scope, prosecution history, infringement theory and the proposed generic’s formulation determine the risk.
Has AbbVie licensed Lupron Depot-PED?
The historical Lupron franchise originated through TAP Pharmaceuticals, a joint venture associated with Abbott Laboratories and Takeda Pharmaceutical. Abbott’s pharmaceutical business was separated into AbbVie in 2013. Takeda retained rights in certain markets and product lines, while commercial ownership and distribution arrangements have varied by geography and time.
Licensing and supply-chain analysis should distinguish:
- U.S. marketing authorization
- Patent ownership
- Manufacturing rights
- Distribution rights
- Regional commercialization
- Pediatric endocrine channel access
A company holding the NDA or commercial brand may not own every historical patent or manufacturing right associated with the product.
What is the Lupron Depot-PED market size and revenue outlook?
Public company disclosures generally do not isolate Lupron Depot-PED revenue from the wider Lupron franchise. Product-level revenue therefore cannot be reliably inferred from AbbVie’s consolidated reporting without prescription, shipment, payer and channel data.
The addressable market is limited by the relatively small number of children diagnosed with central precocious puberty, but treatment duration can extend over several years. Revenue is shaped by:
- Diagnosis rates
- Referral to pediatric endocrinologists
- Treatment initiation age
- Treatment persistence
- Dosing interval
- Buy-and-bill reimbursement
- Specialty pharmacy access
- Prior authorization
- Procedure reimbursement
- Patient assistance programs
- Migration to six-month or annual products
What is the projected market trajectory?
The Lupron Depot-PED segment is likely to decline in unit share over the medium term as longer-acting products gain adoption. The decline should be gradual rather than immediate because Lupron has established clinical familiarity, existing reimbursement pathways and a substantial installed base of prescribers.
A scenario-based projection for the branded product is:
| Scenario |
2025-2027 expectation |
2028-2030 expectation |
| Base case |
Low-single-digit annual revenue decline |
Mid-single-digit annual decline |
| Downside case |
Faster migration to six-month products and price concessions |
High-single-digit decline |
| Upside case |
Stable payer access and limited generic pressure |
Flat to low-single-digit decline |
The base case assumes no major new label expansion, continued availability of competing six-month products, and no immediate multi-generic disruption. A successful complex-generic launch would accelerate price erosion. A manufacturing interruption affecting a competitor could temporarily improve Lupron utilization.
What manufacturing and intellectual-property barriers protect the product?
The principal manufacturing barrier is reproducible long-duration release from injectable microspheres. Small changes in polymer characteristics, solvent removal, particle size or reconstitution can alter exposure and tolerability.
Operational barriers include:
- FDA-compliant sterile manufacturing
- Microsphere process validation
- Reliable supply of pharmaceutical-grade polymer and leuprolide
- Long-term stability data
- Specialized packaging and kit assembly
- Pediatric injection handling
- Pharmacovigilance for a chronic pediatric population
- Reimbursement support for office-administered treatment
These barriers can delay generic competition even after broad patent protection expires.
What are the likely generic launch scenarios?
Scenario 1: No near-term generic launch
Lupron Depot-PED remains commercially relevant because formulation complexity, litigation cost and limited market size deter generic entry. Price remains relatively stable, although payers continue to favor longer-acting alternatives where clinically and economically appropriate.
Scenario 2: Single generic or authorized generic
A single competitor enters after patent settlement or successful litigation. The first launch produces moderate net-price erosion, while the brand retains patients whose physicians prefer the established product or whose plans restrict substitution.
Scenario 3: Multiple complex-generics
Several competitors enter after the relevant formulation and regulatory barriers are resolved. Net pricing falls materially, distribution shifts toward contracted channels, and the brand becomes concentrated in patients with continuity-of-care requirements.
Key Takeaways
- Lupron Depot-PED is an established leuprolide acetate depot product for central precocious puberty.
- Its clinical development program is mature, with current activity centered on monitoring, real-world outcomes and comparisons with longer-acting products.
- Fensolvi, Supprelin LA and Triptodur are the main competitive alternatives.
- Six-month and annual therapies create the largest share risk because they reduce injection frequency.
- The principal remaining barriers are complex depot manufacturing, regulatory requirements and channel execution.
- Product-specific revenue is not separately disclosed in standard public company reporting.
- The medium-term market outlook is gradual erosion rather than an immediate collapse, absent a successful complex-generic launch.
- Orange Book patent and litigation analysis must be performed by NDA, strength, dosage form and patent-use code.
FAQs About Lupron Depot-PED Kit
Is Lupron Depot-PED a biologic requiring biosimilar approval?
No. Leuprolide acetate is a synthetic peptide drug, not a biologic regulated through the biosimilar pathway. A competing product would generally pursue an abbreviated or standalone drug approval pathway, depending on formulation and regulatory requirements.
Is Fensolvi interchangeable with Lupron Depot-PED?
Not automatically. Fensolvi and Lupron Depot-PED contain leuprolide acetate but differ in route, formulation and dosing interval. Substitution depends on FDA interchangeability status, state law, payer policy and prescriber direction.
Does Lupron Depot-PED require prior authorization?
Many commercial and managed-care plans require prior authorization because of the high cost of pediatric endocrine therapies. Criteria commonly include diagnostic confirmation, specialist involvement and documentation of disease progression.
What is the main clinical advantage of Lupron Depot-PED?
Its main advantages are extensive clinical experience, established pediatric endocrine use and availability in monthly and three-month depot schedules. Its main disadvantage is more frequent administration than six-month or annual alternatives.
Can Lupron Depot-PED affect final adult height?
Treatment can slow premature skeletal maturation and may improve predicted adult-height outcomes when central precocious puberty is diagnosed and treated appropriately. Individual outcomes depend on age at treatment, bone age, baseline growth pattern and treatment duration.
References
- U.S. Food and Drug Administration. (2024). Lupron Depot-PED (leuprolide acetate for depot suspension) prescribing information.
- U.S. Food and Drug Administration. (2020). FDA approves Fensolvi for pediatric patients with central precocious puberty.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- ClinicalTrials.gov. (2024). Studies related to central precocious puberty and gonadotropin-releasing hormone agonist therapy.
- AbbVie Inc. (2024). Annual report and Form 10-K.
- Endocrine Society. (2019). Treatment of central precocious puberty and related pediatric endocrine disorders.
